• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与万古霉素耐药肠球菌菌血症持续相关的风险因素和结果。

Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia.

机构信息

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Stanford Antimicrobial Safety and Sustainability Program, Stanford, CA, USA.

出版信息

BMC Infect Dis. 2022 Nov 16;22(1):855. doi: 10.1186/s12879-022-07864-8.

DOI:10.1186/s12879-022-07864-8
PMID:36384497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9670444/
Abstract

BACKGROUND

Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia.

METHODS

This was a single center, retrospective, case-control study of adult patients with a VRE bloodstream infection (BSI). Case patients were those with persistent bacteremia (≥ 4 days despite VRE-directed therapy) and control patients were those with non-persistent bacteremia. Logistic regression was used to assess risk factors associated with persistent VRE BSIs. Secondary outcomes included in-hospital mortality, recurrent bacteremia, and breakthrough bacteremia.

RESULTS

During the study period, 24/108 (22%) patients had persistently positive blood cultures. Risk factors for persistent bacteremia included severe neutropenia (OR 2.13), 4 out of 4 positive index blood cultures (OR 11.29) and lack of source control (OR 11.88). In an unadjusted analysis, no statistically significant differences in in-hospital mortality (58% versus 40%; p = 0.121), recurrent bacteremia (17% versus 6%; p = 0.090), or breakthrough bacteremia (13% versus 7%; p = 0.402) were observed between groups.

CONCLUSION

Patients with severe neutropenia, 4 out of 4 positive index blood culture bottles, and lack of source control were more likely to develop persistent VRE bacteremia despite directed antibiotic treatment.

摘要

背景

先前的研究已经表明,万古霉素耐药肠球菌(VRE)菌血症持续 4 天或以上是死亡的独立预测因素。尽管如此,目前尚无发表的数据来确定那些发生持续性 VRE 菌血症风险最高的患者。

方法

这是一项单中心、回顾性、病例对照研究,纳入了患有 VRE 血流感染(BSI)的成年患者。病例组为持续性菌血症(尽管进行了 VRE 靶向治疗,但持续时间≥4 天)患者,对照组为非持续性菌血症患者。采用逻辑回归评估与持续性 VRE BSI 相关的危险因素。次要结局包括院内死亡率、复发性菌血症和突破性菌血症。

结果

在研究期间,24/108(22%)患者的血培养持续阳性。持续性菌血症的危险因素包括严重中性粒细胞减少症(OR 2.13)、4 个阳性血培养瓶(OR 11.29)和缺乏源头控制(OR 11.88)。在未调整分析中,两组之间的院内死亡率(58%与 40%;p=0.121)、复发性菌血症(17%与 6%;p=0.090)或突破性菌血症(13%与 7%;p=0.402)无统计学显著差异。

结论

尽管进行了靶向抗生素治疗,但严重中性粒细胞减少症、4 个阳性血培养瓶和缺乏源头控制的患者更有可能发生持续性 VRE 菌血症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9d/9670444/e8eb291d0346/12879_2022_7864_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9d/9670444/6bc1adda25a6/12879_2022_7864_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9d/9670444/e8eb291d0346/12879_2022_7864_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9d/9670444/6bc1adda25a6/12879_2022_7864_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc9d/9670444/e8eb291d0346/12879_2022_7864_Fig2_HTML.jpg

相似文献

1
Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia.与万古霉素耐药肠球菌菌血症持续相关的风险因素和结果。
BMC Infect Dis. 2022 Nov 16;22(1):855. doi: 10.1186/s12879-022-07864-8.
2
Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia.万古霉素耐药肠球菌感染及急性白血病伴发热性中性粒细胞减少患者感染和死亡的相关因素。
Leuk Res. 2020 Dec;99:106463. doi: 10.1016/j.leukres.2020.106463. Epub 2020 Oct 18.
3
Risk factors for development of vancomycin-resistant enterococcal bacteremia among VRE colonizers : A retrospective case control study.耐万古霉素肠球菌定植者发生耐万古霉素肠球菌菌血症的危险因素:一项回顾性病例对照研究。
Wien Klin Wochenschr. 2021 May;133(9-10):478-483. doi: 10.1007/s00508-020-01733-7. Epub 2020 Sep 10.
4
Evaluation of risk factors for vancomycin-resistant Enterococcus bacteremia among previously colonized hematopoietic stem cell transplant patients.既往已定植的造血干细胞移植患者中耐万古霉素肠球菌血症危险因素的评估。
Transpl Infect Dis. 2013 Oct;15(5):466-73. doi: 10.1111/tid.12120. Epub 2013 Aug 4.
5
Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection.万古霉素耐药性对中性粒细胞减少症和肠球菌血流感染患者死亡率的影响。
J Infect Dis. 2005 Feb 15;191(4):588-95. doi: 10.1086/427512. Epub 2005 Jan 17.
6
The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections.评估万古霉素耐药性负担时调整肠球菌种属的重要性:一项包括 1000 多例肠球菌血流感染病例的队列研究。
Antimicrob Resist Infect Control. 2018 Nov 14;7:133. doi: 10.1186/s13756-018-0419-9. eCollection 2018.
7
Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study.万古霉素耐药性对中性粒细胞减少的肠球菌血流感染患者死亡率的影响:一项回顾性研究。
BMC Infect Dis. 2013 Oct 29;13:504. doi: 10.1186/1471-2334-13-504.
8
Vancomycin-resistant Enterococcal Bloodstream Infections in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies: Impact of Daptomycin MICs of 3 to 4 mg/L.造血干细胞移植受者和血液系统恶性肿瘤患者中耐万古霉素肠球菌血流感染:达托霉素最低抑菌浓度为3至4mg/L的影响
Clin Ther. 2016 Nov;38(11):2468-2476. doi: 10.1016/j.clinthera.2016.09.011. Epub 2016 Oct 19.
9
Prediction of Bloodstream Infection Due to Vancomycin-Resistant Enterococcus in Patients Undergoing Leukemia Induction or Hematopoietic Stem-Cell Transplantation.白血病诱导或造血干细胞移植患者中万古霉素耐药肠球菌血流感染的预测。
Clin Infect Dis. 2017 Jun 15;64(12):1753-1759. doi: 10.1093/cid/cix232.
10
The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.造血干细胞移植受者中耐万古霉素肠球菌血症的出现。
Leuk Lymphoma. 2014 Dec;55(12):2858-65. doi: 10.3109/10428194.2014.896007. Epub 2014 Mar 24.

引用本文的文献

1
Factors associated with persistent bacteraemia among patients with suspected infective endocarditis.疑似感染性心内膜炎患者持续性菌血症的相关因素。
Infection. 2025 Apr 7. doi: 10.1007/s15010-025-02537-5.
2
Genomic epidemiology of vancomycin-resistant Enterococcus faecium in Eastern Denmark from 2020 to 2022, and identification of vanB Tn1549 insertion sites.2020年至2022年丹麦东部耐万古霉素屎肠球菌的基因组流行病学及vanB Tn1549插入位点的鉴定
Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1425-1432. doi: 10.1007/s10096-025-05091-y. Epub 2025 Apr 1.
3
Systematic screening of 42 vancomycin-resistant Enterococcus faecium strains for resistance, biofilm, and desiccation in simulated microgravity.

本文引用的文献

1
Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I).耐万古霉素肠球菌血症的当代临床与分子流行病学:一项前瞻性多中心队列研究(VENOUS I)
Open Forum Infect Dis. 2021 Dec 23;9(3):ofab616. doi: 10.1093/ofid/ofab616. eCollection 2022 Mar.
2
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.定义持续性金黄色葡萄球菌菌血症:一项前瞻性队列研究的二次分析。
Lancet Infect Dis. 2020 Dec;20(12):1409-1417. doi: 10.1016/S1473-3099(20)30447-3. Epub 2020 Aug 4.
3
The REDCap consortium: Building an international community of software platform partners.
对42株耐万古霉素屎肠球菌进行系统筛选,以研究其在模拟微重力环境下的耐药性、生物膜形成及干燥耐受性。
NPJ Microgravity. 2024 Nov 13;10(1):103. doi: 10.1038/s41526-024-00447-8.
4
Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics.屎肠球菌:进化、适应、发病机制和新兴治疗方法。
Nat Rev Microbiol. 2024 Nov;22(11):705-721. doi: 10.1038/s41579-024-01058-6. Epub 2024 Jun 18.
REDCap 联盟:构建软件平台合作伙伴的国际社区。
J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9.
4
What Is the Best Treatment for Vancomycin-Resistant Enterococcal Bloodstream Infections?耐万古霉素肠球菌血流感染的最佳治疗方法是什么?
Crit Care Med. 2018 Oct;46(10):1700-1703. doi: 10.1097/CCM.0000000000003325.
5
A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections.万古霉素耐药粪肠球菌血流感染的达托霉素与达托霉素和β-内酰胺类抗生素治疗的回顾性临床比较
Sci Rep. 2018 Jan 26;8(1):1632. doi: 10.1038/s41598-018-19986-8.
6
Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia.万古霉素耐药粪肠球菌菌血症的临床特征和治疗结局。
J Microbiol Immunol Infect. 2018 Dec;51(6):705-716. doi: 10.1016/j.jmii.2017.08.025. Epub 2017 Oct 5.
7
Vancomycin-Resistant Enterococci: Therapeutic Challenges in the 21st Century.耐万古霉素肠球菌:21世纪的治疗挑战
Infect Dis Clin North Am. 2016 Jun;30(2):415-439. doi: 10.1016/j.idc.2016.02.006.
8
Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections.时间至关重要:延迟抗生素治疗对医院获得性肠球菌血流感染患者预后的影响
Clin Infect Dis. 2016 May 15;62(10):1242-1250. doi: 10.1093/cid/ciw110. Epub 2016 Mar 3.
9
Therapeutic options for vancomycin-resistant enterococcal bacteremia.耐万古霉素肠球菌菌血症的治疗选择
Expert Rev Anti Infect Ther. 2015 Mar;13(3):363-77. doi: 10.1586/14787210.2015.1001839.
10
Vancomycin-resistant enterococcal bacteremia pharmacotherapy.耐万古霉素肠球菌菌血症的药物治疗
Ann Pharmacother. 2015 Jan;49(1):69-85. doi: 10.1177/1060028014556879. Epub 2014 Oct 28.